Here are five points:
1. The Neuro-Spinal Scaffold is used for acute spinal cord injury treatment.
2. Steven Yocom, DO, professor of neurosurgery and co-director of Cooper Neurological Institute is the principal investigator at the new site.
3. A total of 13 clinical sites are open for enrollment.
4. This is the first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold.
5. The FDA approved the pilot study and it is expected to capture preliminary safety and effectiveness data in five subjects with acute thoracic spinal cord injury.
“Our group has a particular interest in spinal trauma and spinal cord injury,” said Dr. Yocom. “I’m excited that InVivo is approaching the significant unmet medical need in this field with such a novel technology.”
More articles on devices:
Medtronic short interest drops 1.1%: 5 key notes
LDR launches 30-day public offering: 5 key notes
Histogenics reports Q2 $7.6M loss: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
